Compositions of peptide inhibitors of interleukin-23 receptor
AssigneesJanssen Pharmaceutica NV, Protagonist Therapeutics, Inc.
InventorsGiustino Di Pretoro, Dajun SUN, Gopal RAJAN, Geraldine BROECKX, Nathalie MERTENS, Shu LI, Felix LAI, Mohammad MASJEDIZADEH
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
Claims165
A composition comprising:
- a peptide of SEQ ID NO:
- 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the composition;
- and
- one or more pharmaceutically acceptable excipients.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for IL-23 receptor inhibition for treating inflammatory diseases or disorders by delivering a systemically active peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof to a patient in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for inhibition or blocking of IL-23 receptor in blood, blood circulation, tissue, skin or joints for treatment of inflammatory diseases or disorders, which comprises administering:
- an oral dose of therapeutically effective amount of a peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for inhibiting IL-23 receptor in a digestive tract tissue comprising administering an oral dose of a therapeutically effective amount of a peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof to a patient in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method inhibiting the production of IL-17A in a tissue selected from blood, skin, cartilage, synovial membrane, or digestive tract tissue, comprising administering an oral dose of a therapeutically effective amount of a peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof to a patient in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method inhibiting the production of IL-17F in a tissue selected from blood, skin, cartilage, synovial membrane, or digestive tract tissue, comprising administering an oral dose of a therapeutically effective amount of a peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof to a patient in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method inhibiting the production of IL-22 in a tissue selected from blood, skin, cartilage, synovial membrane, or digestive tract tissue, comprising administering an oral dose of a therapeutically effective amount of a peptide Ac-[Pen]*—N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH2 (*Pen-Pen form disulfide bond) (SEQ ID NO:
- 1):
- or a pharmaceutically acceptable salt or solvate form thereof to a patient in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.